Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
Lefèvre
Nicolas
N
Dufour
Dominique
D
Gulbis
Beatrice
B
Lê
Phu-Quoc
PQ
Heijmans
Catherine
C
Ferster
Alina
A
D000755:Anemia, Sickle Cell / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000628:therapy; D000986:Antisickling Agents / Q000008:administration & dosage*; D001783:Blood Flow Velocity / Q000187:drug effects*; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage*; D008297:Male; D020714:Maximum Tolerated Dose; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging; D011446:Prospective Studies; D020521:Stroke / Q000000981:diagnostic imaging / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D017585:Ultrasonography, Doppler, Transcranial
D000986:Antisickling Agents; D006918:Hydroxyurea